| 1. |
- Friman, Styrbjörn, 1948, et al.
(författare)
-
Adjuvant treatment with ursodeoxycholic acid reduces acute rejection after liver transplantation.
- 1992
-
Ingår i: Transplant international : official journal of the European Society for Organ Transplantation. - 0934-0874. ; 5 Suppl 1, s. S187-9
-
Tidskriftsartikel (refereegranskat)abstract
- Acute rejection, occurring with a reported frequency of 50-70%, is still a dominating problem after liver transplantation. Medication with ursodeoxycholic acid (UDCA) has beneficial effects in different cholestatic conditions and has also been shown to reduce HLA class I antigen expression on hepatocytes in patients with PBC. Since August 1989 we have consecutively treated all patients with primary graft function with UDCA (n = 41). Patients transplanted in the first half of 1989 served as a control group (n = 8). All patients in this study were given sequential quadruple drug immunosuppression. The treatment group were given oral UDCA 10 mg/kg per day. During the first postoperative month, 17% of the UDCA-treated patients had an episode of acute rejection compared with 75% of the control patients (P < 0.01). Liver biochemistry tests 1 month postoperatively were significantly better in patients treated with UDCA. The results suggest that adjuvant treatment with UDCA reduces acute liver graft rejection.
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Friman, Styrbjörn, 1948, et al.
(författare)
-
The bile acid independent flow is reduced in the transplanted liver.
- 1992
-
Ingår i: Transplant international : official journal of the European Society for Organ Transplantation. - 0934-0874. ; 5 Suppl 1, s. S163-7
-
Tidskriftsartikel (refereegranskat)abstract
- Bile secretion is an important indicator of liver graft function. Reports on bile formation by the transplanted liver with stable function some months after operation are scarce. In this study bile flow, bile salt secretion rate (BSSR) and biliary clearance of polyethylene glycol (PEG) 900, a marker of canalicular bile flow, were studied in a group of liver-transplanted (LTX) patients (n = 8) 3-6 months after transplantation. A group of cholecystectomized patients with indwelling T-tubes (n = 6) served as a control group. Both groups were treated with oral ursodeoxycholic acid (500 mg/day). On the day of the study bile was drained for 6 h by gravity and four-hourly samples were used in the calculations. The relation between bile flow and BSSR analysed with linear regression showed a reduced bile acid independent flow in the liver-transplanted group (0.11 ml/min) compared with the control group (0.20 ml/min). The relation between biliary clearance of PEG 900 and BSSR showed a significantly steeper slope for the cholecystectomized control patients (1.40 ml/micromol) compared with the liver-transplanted patients (0.30 ml/micromol). We conclude, that in spite of stable graft function with normal liver enzmyes, the transplanted liver has a reduced bile acid independent bile flow. The transplanted liver also has a reduced biliary clearance of PEG 900 indicating a reduced canalicular bile flow. The cause of this impaired bile formation could be due to the influence of the immunosuppressive drug cyclosporin, the result of damage to the liver during preservation and reperfusion or the continuous immunological challenge to the graft.
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
- Olausson, Michael, 1956, et al.
(författare)
-
Adjuvant treatment with ursodeoxycholic acid prevents acute rejection in rats receiving heart allografts.
- 1992
-
Ingår i: Transplant international : official journal of the European Society for Organ Transplantation. - 0934-0874. ; 5 Suppl 1, s. S539-41
-
Tidskriftsartikel (refereegranskat)abstract
- Adjuvant treatment with ursodeoxycholic acid (UDCA) for liver-transplant recipients has been reported to reduce the frequency of acute rejection episodes. To explore this effect further, UDCA was given to rats in an experimental heart transplantation model, with or without concomitant immunosuppressive treatment with antihymocyte globulin (ATG). UDCA was administered orally 7 days before and 14 days after transplantation. Rats treated with UDCA alone or in combination with ATG were compared with untreated controls and ATG-treated recipients. Adjuvant treatment with UDCA was found to induce prolonged graft survival and increase the amount of transplant tolerance in rats. Serum levels of bilirubin and aminotransferases were not altered irrespective of the UDCA dose given. The results indicate that UDCA has an immunomodulatory capacity that might not be restricted to the liver, but also might apply to other transplanted organs as well.
|
|
